KYBORA and ACA Pharma Partner to Accelerate Access to China’s Life Sciences Market Strategic collaboration combines KYBORA’s global biopharma network with ACA Pharma’s 30–90 day Macau registration model to expedite access for rare disease and pediatric therapies in China.  KYBORA and ACA Pharma announced a strategic partnership that combines ACA Pharma’s innovative 30–90 day market-entry strategy via Macau [...]

ACA Pharma Named Exclusive Distributor for Ryanodex® and Barhemsys® in Hong Kong, Macau, Singapore, and Greater China NEW YORK, Oct. 9, 2025 - ACA Pharma is pleased to announce that it has signed an exclusive distribution agreement with Eagle Pharmaceuticals, Inc. for ACA Pharma to commercialize Ryanodex® (dantrolene sodium for injection) and Barhemsys® (amisulpride injection) across

ACA Pharma Named Exclusive Distributor for Feraheme® in Hong Kong, Macau, Greater Bay Area, Mainland China, and Singapore New York, NY — October 23, 2025— ACA Pharma and Azurity Pharmaceuticals are pleased to announce that they have signed an exclusive distribution partnership agreement for ACA Pharma to commercialize Feraheme® (ferumoxytol injection) across Hong Kong, Macau, the

Indian Society of Anaesthesiologists Hosts Nationwide Launch of Ryanodex® in India Perin Healthcare and ACA Pharma collaborate to strengthen malignant hyperthermia readiness across India through the introduction of Eagle Pharmaceutical's Ryanodex® MUMBAI, India and NEW YORK, Nov. 20, 2025 - The Indian Society of Anaesthesiologists (ISA), represented by President Dr. J. Balavenkatasubramanium, Honorary Secretary Dr. Sukhminder Bajwa,

ACA Pharma Announces Major Expansion of RYANODEX® Territory Outside the United States Expanded collaboration significantly broadens ACA Pharma’s ex-U.S. commercialization footprint for RYANODEX® NEW YORK, NY, UNITED STATES, November 24, 2025 - ACA Pharma today announced a significant expansion of their exclusive territory for RYANODEX® (dantrolene sodium) outside the United States. Ryanodex® is indicated for the treatment

ACA Pharma Named Exclusive Distributor for Ferabright™ in Macau, Hong Kong, Singapore, Greater Bay Area and Mainland China NEW YORK, NY, UNITED STATES, January 14, 2026 — ACA Pharma and Azurity Pharmaceuticals are pleased to announce that they have entered into an exclusive distribution partnership under which ACA Pharma will commercialize FerabrightTM (ferumoxytol injection) across Macau,

Ayrmid Appoints ACA Pharma as Exclusive Distributor for Omisirge® across Greater China and Southeast Asia ACA Pharma granted exclusive rights to register and distribute Omisirge across 15 markets, covering both FDA-approved Omisirge indications LONDON – February 9, 2026 – Ayrmid, Ltd. (“Ayrmid” or the “Company”), the parent company of Gamida Cell Inc., today announced that it has